Global Blood Therapeutics Company Profile (NASDAQ:GBT)

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GBT
  • CUSIP: N/A
  • Web: www.globalbloodtx.com
Capitalization:
  • Market Cap: $1.24 billion
  • Outstanding Shares: 43,676,000
Average Prices:
  • 50 Day Moving Avg: $27.87
  • 200 Day Moving Avg: $30.05
  • 52 Week Range: $13.35 - $41.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.73
  • P/E Growth: -0.30
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.53 per share
  • Price / Book: 4.33
Profitability:
  • EBIDTA: ($95,430,000.00)
  • Return on Equity: -38.92%
  • Return on Assets: -36.49%
Debt:
  • Current Ratio: 13.70%
  • Quick Ratio: 13.70%
Misc:
  • Average Volume: 777,373 shs.
  • Beta: 4.22
  • Short Ratio: 8.98
 

Frequently Asked Questions for Global Blood Therapeutics (NASDAQ:GBT)

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its earnings results on Monday, August, 7th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.06. During the same period in the prior year, the company posted ($0.58) EPS. View Global Blood Therapeutics' Earnings History.

When will Global Blood Therapeutics make its next earnings announcement?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Global Blood Therapeutics.

Where is Global Blood Therapeutics' stock going? Where will Global Blood Therapeutics' stock price be in 2017?

12 equities research analysts have issued 12 month target prices for Global Blood Therapeutics' shares. Their predictions range from $23.05 to $83.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $52.73 in the next year. View Analyst Ratings for Global Blood Therapeutics.

What are analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

  • 1. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/16/2017)
  • 3. Cantor Fitzgerald analysts commented, "We are initiating coverage on Global Blood Therapeutics (GBT) with an Overweight rating and a $61/share price target. We believe Global Blood's lead candidate, GBT440, has demonstrated compelling potential for the treatment of sickle cell disease (SCD), based on its reported clinical efficacy and safety data. Moreover, we believe the mechanism of action of oxygen affinity modulation is strongly validated in the scientific literature. Sickle cell disease remains a therapeutic area with a significant unmet need, for which the only approved therapy demonstrating clinical benefit is carcinogenic. Global Blood is currently enrolling up to 400 patients with SCD in its Phase 3 study." (3/15/2017)
  • 4. J P Morgan Chase & Co analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)
  • 5. Instinet analysts commented, "We are initiating coverage of GBT with a Buy rating and $50 price target. We view GBT shares as attractively valued following selloffs in 2016 and expect additional data in 2017 to yield upside by providing further clarity on GBT440's safety and efficacy profile. Specifically, we anticipate upside to GBT shares following a positive readout from the biomarker-driven Phase 2 trials of GBT440 in patients with IPF in 2H17. We expect renewed interest in this readout and the timing of this readout to alleviate the perception that shares are 'dead money' between now and GBT's final Phase 3 read-out in SCD in 1H19. We believe that data from IPF together with updates from the extension studies in SCD will further support GBT440's mechanism of action, better framing the risk around the primary share driver, Phase 3 readout in SCD. The opportunity for IPF remains $16 per share upside to our $50 target price." (3/1/2017)

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

  • Ted W. Love M.D., President, Chief Executive Officer, Director
  • Jeffrey S. Farrow, Chief Financial Officer
  • Peter Radovich, Senior Vice President, Operations
  • Hing L. Sham, Senior Vice President, Research
  • Jung E. Choi, Chief Business and Strategy Officer
  • Tricia Borga Suvari Esq., Chief Legal Officer
  • Charles J. Homcy M.D., Director
  • Willie L. Brown Jr, Independent Director
  • Scott W. Morrison, Independent Director
  • Deval L. Patrick, Independent Director

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who owns Global Blood Therapeutics stock?

Global Blood Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.36%), BlackRock Inc. (7.81%), Vanguard Group Inc. (6.73%), State Street Corp (4.90%), Janus Henderson Group PLC (2.25%) and Redmile Group LLC (1.45%). Company insiders that own Global Blood Therapeutics stock include Deval L Patrick, Eleanor Ramos, John Schembri, Jung Choi, Kevin P Starr and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Who sold Global Blood Therapeutics stock? Who is selling Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, Century Capital Management LLC, OxFORD Asset Management LLP, Tekla Capital Management LLC, PointState Capital LP, Lord Abbett & CO. LLC and ING Groep NV. Company insiders that have sold Global Blood Therapeutics stock in the last year include Deval L Patrick, Jung Choi, Kevin P Starr and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.

Who bought Global Blood Therapeutics stock? Who is buying Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Janus Henderson Group PLC, BlackRock Inc., Vanguard Group Inc., PDT Partners LLC, Goldman Sachs Group Inc., Northern Trust Corp and Sphera Funds Management LTD.. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eleanor Ramos and John Schembri. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy Global Blood Therapeutics stock?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $28.30.


MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Global Blood Therapeutics (NASDAQ:GBT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.73 (86.33% upside)

Analysts' Ratings History for Global Blood Therapeutics (NASDAQ:GBT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Needham & Company LLCInitiated CoverageBuy -> Buy$51.00HighView Rating Details
9/18/2017WedbushReiterated RatingOurperform$73.00MediumView Rating Details
8/14/2017Cowen and CompanyReiterated RatingOutperform$83.00MediumView Rating Details
8/8/2017J P Morgan Chase & CoReiterated RatingOverweight -> Overweight$44.00 -> $46.00MediumView Rating Details
8/4/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$53.00HighView Rating Details
7/11/2017Morgan StanleyReiterated RatingOverweightLowView Rating Details
5/1/2017Janney Montgomery ScottInitiated CoverageBuy$37.00LowView Rating Details
4/17/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$56.00HighView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/15/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$61.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$50.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
9/30/2016Wells Fargo & CompanyInitiated CoverageOutperform$75.00 -> $23.05N/AView Rating Details
2/22/2016Goldman Sachs Group IncLower Price Target$43.00 -> $26.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Global Blood Therapeutics (NASDAQ:GBT)
Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Earnings History by Quarter for Global Blood Therapeutics (NASDAQ GBT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.62)N/AView Earnings Details
8/7/2017Q2 2017($0.61)($0.55)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.64)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Global Blood Therapeutics (NASDAQ:GBT)
Current Year EPS Consensus Estimate: $-2.44 EPS
Next Year EPS Consensus Estimate: $-2.91 EPS

Dividends

Dividend History for Global Blood Therapeutics (NASDAQ:GBT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Global Blood Therapeutics (NASDAQ:GBT)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 86.07%
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.57View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.00View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.00View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Global Blood Therapeutics (NASDAQ:GBT)
Latest Headlines for Global Blood Therapeutics (NASDAQ:GBT)
Source:
DateHeadline
streetinsider.com logoUPDATE: Needham & Company Starts Global Blood Therapeutics (GBT) at Buy; GBT440 Could Transform SSD ... - StreetInsider.com
www.streetinsider.com - September 22 at 5:56 PM
finance.yahoo.com logoOne Thing To Consider Before Buying Global Blood Therapeutics Inc (GBT)
finance.yahoo.com - September 22 at 12:35 PM
americanbankingnews.com logoGlobal Blood Therapeutics (GBT) versus Its Peers Head-To-Head Contrast
www.americanbankingnews.com - September 21 at 10:13 AM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Receives New Coverage from Analysts at Needham & Company LLC
www.americanbankingnews.com - September 20 at 5:46 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Receives Ourperform Rating from Wedbush
www.americanbankingnews.com - September 18 at 4:34 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - September 16 at 7:44 PM
finance.yahoo.com logoGlobal Blood Therapeutic Sees IBD RS Rating Climb To 71
finance.yahoo.com - September 14 at 7:35 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 2:50 PM
americanbankingnews.com logo Brokerages Anticipate Global Blood Therapeutics, Inc. (GBT) Will Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - September 9 at 10:24 AM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Announces Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of SCD
www.streetinsider.com - September 7 at 4:58 AM
nasdaq.com logoGlobal Blood Therapeutics Receives Rare Pediatric Disease ... - Nasdaq
www.nasdaq.com - September 6 at 6:53 PM
globenewswire.com logoGlobal Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 6:53 PM
finance.yahoo.com logoGlobal Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
finance.yahoo.com - September 6 at 6:53 PM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Announces Rare Pediatric Disease Designation from FDA for GBT440 for Treatment ... - StreetInsider.com
www.streetinsider.com - September 6 at 12:56 AM
finance.yahoo.com logoGlobal Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
finance.yahoo.com - September 6 at 12:56 AM
americanbankingnews.com logoJung Choi Sells 3,000 Shares of Global Blood Therapeutics, Inc. (GBT) Stock
www.americanbankingnews.com - September 5 at 8:34 PM
finance.yahoo.com logoGlobal Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
finance.yahoo.com - August 31 at 12:12 AM
americanbankingnews.com logoOncoGenex Pharmaceuticals (ACHV) vs. Global Blood Therapeutics (GBT) Head-To-Head Comparison
www.americanbankingnews.com - August 30 at 4:26 PM
seekingalpha.com logoGlobal Blood files for $125M mixed shelf offering
seekingalpha.com - August 25 at 5:34 AM
seekingalpha.com logoROTY Edition 1 Volume 23: Spotlight On SteadyMed And Global Blood Therapeutics - Seeking Alpha
seekingalpha.com - August 21 at 11:25 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - August 21 at 8:06 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Upgraded at BidaskClub
www.americanbankingnews.com - August 20 at 7:00 PM
seekingalpha.com logoGlobal Blood Therapeutics (GBT) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 17 at 8:14 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM
streetinsider.com logoCowen Reiterates Outperform on Global Blood Therapeutics (GBT) After Meeting with Management - StreetInsider.com
www.streetinsider.com - August 14 at 7:17 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - August 14 at 5:30 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Lowered to Sell at BidaskClub
www.americanbankingnews.com - August 13 at 11:58 AM
seekingalpha.com logoThe Investment Case For Global Blood Therapeutics
seekingalpha.com - August 11 at 7:24 PM
finance.yahoo.com logoGlobal Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 7:07 PM
nasdaq.com logoGlobal Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - August 8 at 6:39 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 7 at 9:16 PM
finance.yahoo.com logoGlobal Blood reports 2Q loss
finance.yahoo.com - August 7 at 9:10 PM
finance.yahoo.com logoGlobal Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 4:07 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Initiates Coverage on Global Blood Therapeutics, Inc. (NASDAQ:GBT)
www.americanbankingnews.com - August 6 at 8:28 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - August 5 at 8:02 PM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For August 4, 2017 - Benzinga
www.benzinga.com - August 4 at 7:14 PM
streetinsider.com logoUPDATE: Oppenheimer Starts Global Blood Therapeutics (GBT) at Outperform, Possible Takeout Candidate - StreetInsider.com
www.streetinsider.com - August 4 at 7:14 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Expected to Post Earnings of -$0.60 Per Share
www.americanbankingnews.com - August 3 at 4:14 PM
nasdaq.com logoGBT Crosses Below Key Moving Average Level
www.nasdaq.com - August 1 at 7:32 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Director Sells $803,203.57 in Stock
www.americanbankingnews.com - July 27 at 7:42 PM
globenewswire.com logoGlobal Blood Therapeutics Announces New Employment Inducement Grants - GlobeNewswire (press release)
globenewswire.com - July 27 at 12:32 AM
nasdaq.com logoGlobal Blood Therapeutics Announces New Employment Inducement Grants - Nasdaq
www.nasdaq.com - July 26 at 7:32 PM
finance.yahoo.com logoGlobal Blood Therapeutics Announces New Employment Inducement Grants
finance.yahoo.com - July 26 at 7:32 PM
americanbankingnews.com logoInsider Selling: Global Blood Therapeutics, Inc. (GBT) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - July 25 at 7:51 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - July 23 at 5:34 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 6:51 PM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Short Interest Up 48.5% in June
www.americanbankingnews.com - July 15 at 7:22 AM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.60 Per Share
www.americanbankingnews.com - July 12 at 10:18 AM
americanbankingnews.com logoGlobal Blood Therapeutics, Inc. (GBT) Earns Overweight Rating from Morgan Stanley
www.americanbankingnews.com - July 11 at 7:08 AM
streetinsider.com logoGlobal Blood Therapeutics (GBT) Expands Phase 2a HOPE-KIDS 1 Study into Younger Pediatric - StreetInsider.com
www.streetinsider.com - July 10 at 6:53 PM

Social

Chart

Global Blood Therapeutics (GBT) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff